Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment
with irinotecan.
PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing
diarrhea in patients who are receiving irinotecan for metastatic colon cancer.